arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

TREACE MEDICAL CONCEPTS, INC.

TMCI
$4.77 ▲ +0.36 (+8.29%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

TREACE MEDICAL CONCEPTS, INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $308.1M
Dividend Yield
Revenue Growth -10.2%
Op. Margin -36.4%
ROIC -10.2%
FCF / Share $0.06
Trailing P/E
Price / Book 4.0x
FCF Yield 1.4%
Debt / Equity 0.75
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$47.20M
↓ -10.2%
Net Income Profit after all expenses
$-17.96M
↓ -12.8%
Operating Margin Operating profit as % of sales
-36.4%
↓ -284.0% 9th
FCF / Share Free cash flow per share
$0.06
↑ +518.8%
Long-Term Debt Long-term obligations
$55.82M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
13
Financial Health
36
Cash Quality
40

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters